F-1/A: Cuprina Holdings Files for $15.9 Million IPO to Expand Wound Care and Cosmeceutical Business

Cuprina Holdings, a Singapore-based biomedical company, is seeking to raise capital through an initial public offering to expand its operations in chronic wound care and cosmeceuticals.

Summary

• Cuprina Holdings (Cayman) Limited has filed an amendment to its Form F-1 registration statement for an initial public offering.
• The company plans to offer 3,750,000 Class A Ordinary Shares with an anticipated initial public offering price between US$4.00 and US$4.50 per share.
• The midpoint of this range suggests a price of US$4.25 per share, potentially raising US$15,937,500 before expenses.
• Cuprina has applied to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol CUPR.
• The offering's closing is contingent upon Nasdaq's final approval of the listing application.
• Immediately after the offering, Cuprina will have 3,915,000 Class A Ordinary Shares and 14,085,000 Class B Ordinary Shares issued and outstanding.
• The company will continue to be a controlled company under Nasdaq rules, as Cuprina Holding Pte. Ltd. will hold more than 50% of the aggregate voting power.
• Cuprina is an emerging growth company and an exempted company incorporated in the Cayman Islands, conducting operations in Singapore, Hong Kong, Saudi Arabia, Malaysia and mainland China through its subsidiaries.
• For the years ended December 31, 2021, 2022 and 2023, Cuprina's revenue amounted to S$58,504, S$56,599 and S$100,773 (US$76,424), respectively, while it recorded net losses of S$519,686, S$1,094,516 and S$1,119,555 (US$849,048), respectively.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has innovative products, it also faces financial challenges and risks associated with its early stage and dependence on key agreements.

Positives

• Cuprina has strategic plans to expand sales and establish physical operations in key regions.
• The company has attained ISO 13485:2016 standards for its manufacturing facility in Singapore.
• Cuprina has access to innovative technology through licensing agreements and research collaboration with Nanyang Technological University.
• The company is working towards obtaining compliance with 21 CFR Part 820 to secure FDA 510(k) clearance.

Negatives

• Cuprina has a history of losses and expects to incur losses in the foreseeable future.
• The company recorded net current liabilities as of December 31, 2021, 2022 and 2023.
• Cuprina had net operating cash outflows for the years ended December 31, 2021, 2022 and 2023.

Risks

• An active trading market for Cuprina's Class A Ordinary Shares may not be established.
• The trading price of Cuprina's Class A Ordinary Shares may be volatile.
• Cuprina may not be able to develop new products that are competitive or successful.
• The development and sale of certain pipeline products are heavily dependent on agreements with NTU.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy and unpredictable.
• The company relies heavily on R&D partners for know-how on design, manufacturing methods and formulation of products.
• The company is dependent on a few major customers and suppliers.

Future Outlook

Cuprina plans to expand its sales and establish physical operations in Southeast Asia, the Middle East, and mainland China, and to introduce new cosmeceutical product candidates between 2024 and 2028.

Industry Context

The announcement reflects a growing trend of biomedical companies seeking public funding to expand their operations in the burgeoning wound care and cosmeceutical markets, driven by an aging population and increasing prevalence of chronic diseases.

Comparison to Industry Standards

• It is difficult to compare Cuprina's financial performance directly to industry standards due to its early stage and unique product focus.
• Larger, established wound care companies like Smith & Nephew and Mlnlycke Health Care have significantly higher revenues and broader product portfolios.
• However, Cuprina's focus on nature-derived bioactives and sustainable practices could differentiate it from competitors.
• The company's reliance on a single product line (MEDIFLY) for a significant portion of its revenue poses a risk compared to companies with more diversified revenue streams.

Related Party Transactions

• Cuprina Holding Pte. Ltd. provided advances to the company for working capital purposes.
• Jimmy Lee Peng Siew, an ultimate beneficial shareholder, provided advances to the company for working capital purposes.
• The company has entered into a joint venture agreement with a local medical services company in Saudi Arabia.
• The company has entered into an exclusive distribution and cooperation and profit-sharing agreement with Advanced Biotech and Engineering Limited in Hong Kong.
• The company has entered into an Agreement to Collaborate and Protect Confidentiality with Nanao (Beijing) Hospital Management Co., Ltd. in mainland China.
• The company has entered into a licensing agreement and an industry research collaboration agreement with Nanyang Technological University.

Stakeholder Impact

• Shareholders will experience dilution as a result of the IPO.
• Employees may benefit from the company's growth and expansion plans.
• Customers may benefit from the development of new and innovative products.
• Suppliers may benefit from increased demand for raw materials and components.
• Creditors may be impacted by the company's ability to repay its debts.

Next Steps

• Obtain Nasdaq approval for listing.
• Complete the initial public offering.
• Expand sales and establish physical operations in new regions.
• Continue research and development of pipeline products.
• Obtain FDA 510(k) clearance for chronic wound care products.

Key Dates

Keywords

Cuprina Holdings, IPO, Class A Ordinary Shares, biomedical, biotechnology, chronic wounds, cosmeceuticals, MEDIFLY, maggot debridement therapy, Nasdaq